Quantcast

Latest DNA vaccination Stories

2011-05-05 03:00:00

BLUE BELL, Pa., May 5, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success." The article was co-authored by Dr. Niranjan Sardesai, Inovio's Senior Vice President, Research...

2011-05-04 03:00:00

BLUE BELL, Pa., May 4, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at two scientific conferences: 15th Annual Conference on Women's Health Care IssuesHosted by International Infectious Disease Society for Obstetrics and Gynecology-USAWeill Greenberg CenterNew York, NY 10021 Inovio PresentationMark...

2011-04-29 03:00:00

BLUE BELL, Pa., April 29, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at three investor conferences: JMP Securities Research ConferenceSan Francisco, CA, May 9-11, 2011The Ritz-Carlton, San Francisco Inovio PresentationDr. J. Joseph Kim, Ph.D., President & CEOMay 9, 201110:30 AM...

2011-04-18 03:00:00

BLUE BELL, Pa., April 18, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. (Euronext Paris: FR0005175080) and ChronTech Pharma AB (CTEC.ST) to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I clinical study. It is common to follow...

2011-04-13 00:00:27

Overcoming the gene silencing barrier opens doors for gene therapy. Lincoln, NE (PRWEB) April 12, 2011 NTC today announced the award of a Small Business Innovation Research (SBIR) Phase II grant award from the National Institute of General Medical Sciences. The award represents a continuation of a Phase I study, which initially demonstrated the feasibility of overcoming transgene silencing, previously, a major barrier to successful gene therapy. In addition to anti-silencing elements, the...

2011-04-13 00:00:27

The Company's adjuvant gives 70% prevention of infection in primates Atlanta, GA (Vocus/PRWEB) April 12, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN). Specifically, the HVTN plans to clinically test a novel vaccine...

2011-04-11 06:00:00

ATLANTA, April 11, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN). Specifically, the HVTN plans to clinically test a novel vaccine product developed by GeoVax scientists that expresses human...

2011-04-04 22:24:21

Killer T cells begin to divide en route to virus-infected tissue, allowing them to hit the ground running when they arrive, according to a study published online on April 4 in the Journal of Experimental Medicine (www.jem.org). Cytotoxic ("killer") T cells (CTL) defend the body against viruses by attacking infected cells. In order to outpace a rapidly replicating virus, CTL must bolster their numbers via cell division. But early cell division is a slow process, requiring nearly a full day for...

2011-04-04 05:02:00

SAN DIEGO, April 4, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011. (Logo:...

2011-03-21 03:00:00

BLUE BELL, Pa., March 21, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a U.S. Department of Defense Small Business Innovation Research Grant to test the feasibility of delivering DNA vaccines by intradermal electroporation simultaneously to two or more spatially distinct sites on the body. The purpose of such a prototype...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related